DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,042 filers reported holding DANAHER CORPORATION in Q1 2016. The put-call ratio across all filers is 0.83 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,334,712 | -4.3% | 13,441 | -7.4% | 0.35% | -2.2% |
| Q2 2023 | $3,483,840 | -7.0% | 14,516 | -2.4% | 0.36% | -9.3% |
| Q1 2023 | $3,747,079 | -6.0% | 14,867 | -1.0% | 0.40% | -11.8% |
| Q4 2022 | $3,986,343 | +4.5% | 15,019 | +1.7% | 0.45% | -5.5% |
| Q3 2022 | $3,816,000 | +5.3% | 14,773 | +3.4% | 0.48% | +6.7% |
| Q2 2022 | $3,623,000 | -12.6% | 14,292 | +1.2% | 0.45% | -6.7% |
| Q1 2022 | $4,143,000 | -6.6% | 14,125 | +4.8% | 0.48% | -15.5% |
| Q4 2021 | $4,435,000 | +7.5% | 13,480 | -0.5% | 0.57% | -5.5% |
| Q3 2021 | $4,124,000 | +13.1% | 13,547 | -0.3% | 0.60% | +4.7% |
| Q2 2021 | $3,645,000 | +15.6% | 13,584 | -3.0% | 0.57% | +6.7% |
| Q1 2021 | $3,153,000 | -0.3% | 14,009 | -1.5% | 0.54% | -9.0% |
| Q4 2020 | $3,161,000 | +4.5% | 14,229 | +1.2% | 0.59% | -9.1% |
| Q3 2020 | $3,026,000 | +19.2% | 14,054 | -2.1% | 0.65% | +6.7% |
| Q2 2020 | $2,538,000 | +21.4% | 14,354 | -5.0% | 0.61% | +5.6% |
| Q1 2020 | $2,091,000 | -10.1% | 15,109 | -0.3% | 0.58% | +9.3% |
| Q4 2019 | $2,325,000 | +6.9% | 15,149 | +0.7% | 0.53% | -0.9% |
| Q3 2019 | $2,174,000 | -0.6% | 15,049 | -1.6% | 0.53% | -1.8% |
| Q2 2019 | $2,187,000 | +6.9% | 15,299 | -1.3% | 0.54% | +1.9% |
| Q1 2019 | $2,046,000 | +22.7% | 15,499 | -4.2% | 0.53% | +13.2% |
| Q4 2018 | $1,668,000 | -6.0% | 16,174 | -0.9% | 0.47% | -2.9% |
| Q3 2018 | $1,774,000 | +8.5% | 16,324 | -1.5% | 0.48% | +7.3% |
| Q2 2018 | $1,635,000 | -2.2% | 16,572 | -2.9% | 0.45% | -2.6% |
| Q1 2018 | $1,671,000 | -1.6% | 17,071 | -6.7% | 0.46% | +5.7% |
| Q4 2017 | $1,698,000 | +2.6% | 18,296 | -5.1% | 0.44% | -3.1% |
| Q3 2017 | $1,655,000 | -0.5% | 19,289 | -2.1% | 0.45% | -3.6% |
| Q2 2017 | $1,663,000 | +6.0% | 19,704 | -2.2% | 0.47% | +2.9% |
| Q1 2017 | $1,569,000 | 0.0% | 20,154 | 0.0% | 0.46% | +1.1% |
| Q4 2016 | $1,569,000 | -1.4% | 20,154 | -0.7% | 0.45% | -1.3% |
| Q3 2016 | $1,592,000 | -23.7% | 20,304 | -1.7% | 0.46% | -26.8% |
| Q2 2016 | $2,087,000 | +6.2% | 20,659 | -0.3% | 0.62% | +5.1% |
| Q1 2016 | $1,966,000 | -8.3% | 20,727 | -10.2% | 0.59% | -5.7% |
| Q4 2015 | $2,143,000 | +4.6% | 23,077 | -4.0% | 0.63% | +1.0% |
| Q3 2015 | $2,048,000 | -55.7% | 24,032 | -55.5% | 0.62% | -12.4% |
| Q2 2015 | $4,622,000 | +83.9% | 54,012 | +82.5% | 0.71% | -8.1% |
| Q1 2015 | $2,513,000 | -6.6% | 29,601 | -5.7% | 0.78% | -6.2% |
| Q4 2014 | $2,690,000 | +7.4% | 31,386 | -4.8% | 0.83% | +14.9% |
| Q3 2014 | $2,505,000 | -7.5% | 32,974 | -4.1% | 0.72% | -5.9% |
| Q2 2014 | $2,707,000 | +3.2% | 34,381 | -1.7% | 0.76% | +0.3% |
| Q1 2014 | $2,624,000 | -9.8% | 34,981 | -7.1% | 0.76% | -12.7% |
| Q4 2013 | $2,908,000 | +9.0% | 37,670 | -2.2% | 0.87% | -10.2% |
| Q3 2013 | $2,669,000 | +3.7% | 38,505 | -5.3% | 0.97% | +13.4% |
| Q2 2013 | $2,573,000 | – | 40,648 | – | 0.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |